Therapeutical Class：Glycopeptide, inhibits bacterial cell wall synthesis by blocking glycopeptides polymerization through binding tightly to D-alanyl-D-alanine

Indication：Infections caused by staphylococcal species and streptococcal species ; used orally for staphylococcal enterocolitis or for antibiotic-associated pseudomembranous colitis produced by C. difficile.

Administraton：

Adults: IV 30-60 mg/kg/day (usually 2-3 g/day) in 2-4 divided doses.

Children: IV 10-15 mg/kg q6h, max 2 g/day.

Renal impairment: loading dose: 15 mg/kg; maintenance dose as following:

Ccr 20-49 ml/min, 15-20 mg/kg/dose (usual: 750-1500 mg) qd; Ccr <20 ml/min, will need longer intervals.

Adverse Effect：Chills, fever, nausea, phlebitis, transient systolic hypotension(>10%) caused by rapid infusion, red man syndrome(>10%), ototoxicity(<1%), nephrotoxicity (<1%), eosinophilia(1-10%), neutropenia(1-10%), urticarial rash.

Pregnancy Risk：C

Supply：Vancomycin XE “Vancomycin” Inj 500mg（泛可黴素靜脈注射劑Hospira）＜10998＞